MARKET

ZGNX

Zogenix
ZGNX
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-3.8910
18.25
8.35
1,493,868,854.48
BRIEF-UCB SA - UCB Completes Acquisition Of Zogenix, Inc.
reuters.com · 03/07 17:02
Merger Arbitrage Mondays - Healthcare Trust Of America To Combine With Healthcare Realty Trust
Merger activity increased last week with six new deals announced and six deals completed. Three of the six new deals announced were potential deals in the works. Healthcare Trust of America (NYSE: HTA)
Benzinga · 03/07 15:33
Update: Zogenix Completes $1.9 Billion Buyout by UCB; Shares Delisted From Nasdaq
MT Newswires · 03/07 14:48
UCB Closes Zogenix Acquisition for Nearly $1.9 Billion
MT Newswires · 03/07 13:38
Zogenix To Present New Long-term Data On FINTEPLA (fenfluramine) In Lennox-Gastaut Syndrome (LGS) At AAN 2022 From April 2-7
Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for
Benzinga · 03/04 13:06
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patientsLGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to af...
GlobeNewswire · 03/04 13:00
BRIEF-UCB Says HSR Waiting Period For Zogenix Acquisition Expired
reuters.com · 03/04 07:13
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies.
Benzinga · 03/02 12:08
More
No Data
Learn about the latest financial forecast of ZGNX. Analyze the recent business situations of Zogenix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

11.11%Strong Buy
11.11%Buy
77.78%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ZGNX stock price target is 36.57 with a high estimate of 62.00 and a low estimate of 17.00.
High62.00
Average36.57
Low17.00
Current 26.68
EPS
Actual
Estimate
-0.84-0.63-0.42-0.21
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 250
Institutional Holdings: 71.09M
% Owned: 126.97%
Shares Outstanding: 55.99M
TypeInstitutionsShares
Increased
36
3.35M
New
30
2.90M
Decreased
54
2.93M
Sold Out
19
1.26M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.62%
Pharmaceuticals & Medical Research
+0.64%
Key Executives
Non-Executive Chairman/Independent Director
Cam Garner
President/Chief Executive Officer/Director
Stephen Farr
Chief Financial Officer/Executive Vice President/Treasurer/Secretary
Michael Smith
Executive Vice President/General Counsel/Secretary
Shawnte Mitchell
Executive Vice President
Gail Farfel
Executive Vice President
Bradley Galer
Executive Vice President
Ashish Sagrolikar
Independent Director
Louis Bock
Independent Director
James Breitmeyer
Independent Director
Caroline Loewy
Independent Director
Erle Mast
Independent Director
Mary Stutts
Independent Director
Renee Tannenbaum
Independent Director
Denelle Waynick
Independent Director
Mark Wiggins
No Data
No Data

Webull offers kinds of Zogenix stock information, including NASDAQ:ZGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZGNX stock methods without spending real money on the virtual paper trading platform.